Nová doporučení pro léčbu lupusové nefritidy
Authors:
O. Derner; Z. Hrušková; R. Ryšavá; V. Tesař
Authors place of work:
Klinika nefrologie 1. LF UK a VFN, P raha
Published in the journal:
Čes. Revmatol., 29, 2021, No. 2, p. 78-85.
Category:
Recomendation
Summary
We show an overview of joint recommendations of EULAR (European League Against Rheumatism) and ERA-EDTA (European Renal Association-European Dialysis and Transplant Association) for diagnostics, treatment and monitoring of patients with lupus nephritis. The text also comments on some recent data published after these guidelines went to press.
Zdroje
- Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71(11): 1771–1782.
- Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79(6): 713–723.
- de Rosa M, Rocha AS, De Rosa G, Dubinsky D, Almaani SJ, Rovin BH, et al. Low-Grade Proteinuria Does Not Exclude Significant Kidney Injury in Lupus Nephritis. Kidney International Reports 2020; 5(7): 1066–1068.
- Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78(9): 1151–1159.
- Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of health activity and chronicity indices. Kidney Int 2018; 93: 789–796.
- Zavada J, Pesickova S, Rysava R, Olejarova M, Horak P, Hrncir Z, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 2010; 19: 1281–1289.
- Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015; 162(1): 18–26.
- Tamirou F, Lauwerys BR, Dall’Era M, Mackay M, Rovin B, Cervera R, et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the maintain nephritis trial. Lupus Sci Med 2015; 2: e000123.
- Dall’Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort. Arthritis Rheumatol 2015; 67: 1305–1313.
- Mackay M, Dall’Era M, Fishbein J, Kalunian K, Lesser M, Rovin BH, et al. Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis Rheumatol 2019; 71(3): 411–419.
- Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013; 22(6): 574–582.
- Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al. Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin J Am Soc Nephrol 2018; 13(10): 1502–1509.
- Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 2020; 383(12): 1117–1128.
- Houssiau FA, D’Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 2010; 69: 2083–2089.
- Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886–1895.
- de Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 2018; 94(4): 788–794.
- Malvar A, Alberton V, Lococo B, Ferrari M, Delgado P, Nagaraja HN, et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int 2020; 97(1): 156–162.
- Mejia-Vilet JM, Zhang XL, Cruz C, Cano-Verduzco ML, Shapiro JP, Nagaraja HN, et al. Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. J Am Soc Nephrol 2020; 31(6): 1335–1347.
- Jorge A, Wallace ZS, Lu N, Zhang Y, Choi HK. Renal Transplantation and Survival Among Patients With Lupus Nephritis: A Cohort Study. Ann Intern Med 2019; 170(4): 240–247.
Štítky
Dermatology & STDs Paediatric rheumatology RheumatologyČlánok vyšiel v časopise
Czech Rheumatology
2021 Číslo 2
Najčítanejšie v tomto čísle
- NOVÁ DOPORUČENÍ PRO PACIENTY s dnou a zvýšenou hladinou kyseliny močové v krvi
- Nová doporučení pro léčbu lupusové nefritidy
- Overview of biomarkers and their relationship to axial spondyloarthritis associated with idiopathic inflammatory bowel diseases
- Doporučení České revmatologické společnosti pro farmakologickou léčbu axiálních spondyloartritid